Leptoprol

Leuprorelin, the active ingredient in Leptoprol, is a Gonadotropin‑releasing hormone (GnRH) agonist presented as a subcutaneous formulation for injection use. It is employed in the management of hormone‑dependent cancers and selected reproductive disorders in adult patients.

GNH USA supplies Leptoprol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides regulatory support for cross‑border distribution. Leptoprol is shipped in temperature‑controlled packaging to maintain product integrity during transit.

Leuprorelin is a GnRH agonist used to modulate hormone‑dependent disease pathways.

- Prostate cancer: lowers testosterone to inhibit tumor progression. - Breast cancer: suppresses estrogen production in hormone‑sensitive tumors. - Endometriosis: reduces pelvic estrogen levels to alleviate pain and lesion growth. - Uterine fibroids: diminishes estrogen‑driven fibroid size and symptoms. - Precocious puberty: halts premature activation of the hypothalamic‑pituitary‑gonadal axis.

Leuprorelin may cause a range of adverse reactions, most of which are related to hormonal changes and injection site irritation.

Common Side Effects: - Hot flashes: sudden feeling of warmth and sweating. - Injection site reactions: pain, redness, or swelling at the injection site. - Headache: mild to moderate intensity. - Fatigue: generalized tiredness. - Mood changes: irritability or depressive symptoms. - Decreased libido: reduced sexual desire.

Serious or Rare Side Effects: - Osteoporosis: loss of bone density with long‑term use. - Cardiovascular events: increased risk of thromboembolism or myocardial infarction. - Severe allergic reaction: anaphylaxis, angioedema, or rash. - Adrenal insufficiency: impaired cortisol production. - Pituitary apoplexy: rare hemorrhage within the pituitary gland.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor ongoing safety.

- Cardiovascular assessment: screen for existing heart disease or clotting disorders. - Bone health monitoring: consider baseline densitometry and calcium/vitamin D supplementation. - Liver function evaluation: adjust use if significant hepatic impairment is present. - Hypersensitivity check: avoid in patients with known allergy to leuprorelin or excipients. - Pregnancy and contraception: contraindicated in pregnancy; ensure effective contraception during treatment. - Store at 2-8 °C: keep refrigerated, protect from light, do not freeze or shake.

Leuprorelin can interact with other medicines that influence hormonal pathways or metabolic enzymes.

Major Interactions (Avoid): - Concurrent GnRH agonists or antagonists: additive hormonal suppression may cause severe hypo‑gonadism. - Estrogen‑containing contraceptives: reduced contraceptive efficacy. - Strong CYP3A4 inducers (e.g., rifampicin): may lower leuprorelin exposure.

Moderate Interactions (Monitor Closely): - Anticoagulants: monitor for altered bleeding risk due to hormonal effects. - Antidepressants: may exacerbate mood‑related side effects. - Bisphosphonates: coordinate when managing leuprorelin‑induced bone loss. - Chemotherapy agents: schedule to avoid overlapping toxicities.